PURPOSE: The CpG island methylator phenotype (CIMP) may be associated with development of malignancy through coordinated inactivation of tumor suppressor and tumor-related genes (TRG) and methylation of multiple noncoding, methylated-in-tumor (MINT) loci. These epigenetic changes create a distinct CIMP pattern that has been linked to recurrence and survival in gastrointestinal cancers. Because epigenetic inactivation of TRGs also has been shown in malignant melanoma, we hypothesized the existence of a clinically significant CIMP in cutaneous melanoma progression. EXPERIMENTAL DESIGN: The methylation status of the CpG island promoter region of TRGs related to melanoma pathophysiology (WIF1, TFPI2, RASSF1A, RARbeta2, SOCS1, and GATA4) and a panel of MINT loci (MINT1, MINT2, MINT3, MINT12, MINT17, MINT25, and MINT31) in primary and metastatic tumors of different clinical stages (n=122) was assessed. RESULTS: Here, we show an increase in hypermethylation of the TRGs WIF1, TFPI2, RASSF1A, and SOCS1 with advancing clinical tumor stage. Furthermore, we find a significant positive association between the methylation status of MINT17, MINT31, and TRGs. The methylation status of MINT31 is associated with disease outcome in stage III melanoma. CONCLUSIONS: These findings show the significance of a CIMP pattern that is associated with advancing clinical stage of malignant melanoma. Future prospective large-scale studies may determine if CIMP-positive primary melanomas are at high risk of metastasis or recurrence.
PURPOSE: The CpG island methylator phenotype (CIMP) may be associated with development of malignancy through coordinated inactivation of tumor suppressor and tumor-related genes (TRG) and methylation of multiple noncoding, methylated-in-tumor (MINT) loci. These epigenetic changes create a distinct CIMP pattern that has been linked to recurrence and survival in gastrointestinal cancers. Because epigenetic inactivation of TRGs also has been shown in malignant melanoma, we hypothesized the existence of a clinically significant CIMP in cutaneous melanoma progression. EXPERIMENTAL DESIGN: The methylation status of the CpG island promoter region of TRGs related to melanoma pathophysiology (WIF1, TFPI2, RASSF1A, RARbeta2, SOCS1, and GATA4) and a panel of MINT loci (MINT1, MINT2, MINT3, MINT12, MINT17, MINT25, and MINT31) in primary and metastatic tumors of different clinical stages (n=122) was assessed. RESULTS: Here, we show an increase in hypermethylation of the TRGs WIF1, TFPI2, RASSF1A, and SOCS1 with advancing clinical tumor stage. Furthermore, we find a significant positive association between the methylation status of MINT17, MINT31, and TRGs. The methylation status of MINT31 is associated with disease outcome in stage III melanoma. CONCLUSIONS: These findings show the significance of a CIMP pattern that is associated with advancing clinical stage of malignant melanoma. Future prospective large-scale studies may determine if CIMP-positive primary melanomas are at high risk of metastasis or recurrence.
Authors: C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Mingzhou Guo; Yoshimitsu Akiyama; Michael G House; Craig M Hooker; Elizabeth Heath; Edward Gabrielson; Stephen C Yang; Yu Han; Stephen B Baylin; James G Herman; Malcolm V Brock Journal: Clin Cancer Res Date: 2004-12-01 Impact factor: 12.531
Authors: Julien Mazieres; Biao He; Liang You; Zhidong Xu; Amie Y Lee; Iwao Mikami; Noemi Reguart; Rafael Rosell; Frank McCormick; David M Jablons Journal: Cancer Res Date: 2004-07-15 Impact factor: 12.701
Authors: Marius Van Rijnsoever; Hany Elsaleh; David Joseph; Kieran McCaul; Barry Iacopetta Journal: Clin Cancer Res Date: 2003-08-01 Impact factor: 12.531
Authors: Dave S B Hoon; Mia Spugnardi; Christine Kuo; Sharon K Huang; Donald L Morton; Bret Taback Journal: Oncogene Date: 2004-05-13 Impact factor: 9.867
Authors: R C Sobti; Neha Singh; Showket Hussain; Vanita Suri; Raje Nijhawan; A C Bharti; Mausumi Bharadwaj; B C Das Journal: Cell Oncol (Dordr) Date: 2011-09-21 Impact factor: 6.730
Authors: Aithne Atkinson; Alexander Renziehausen; Hexiao Wang; Cristiana Lo Nigro; Laura Lattanzio; Marco Merlano; Bhavya Rao; Lynda Weir; Alan Evans; Rubeta Matin; Catherine Harwood; Peter Szlosarek; J Geoffrey Pickering; Colin Fleming; Van Ren Sim; Su Li; James T Vasta; Ronald T Raines; Mathieu Boniol; Alastair Thompson; Charlotte Proby; Tim Crook; Nelofer Syed Journal: J Invest Dermatol Date: 2018-11-16 Impact factor: 8.551
Authors: Ilse Van der Auwera; Wayne Yu; Liping Suo; Leander Van Neste; Peter van Dam; Eric A Van Marck; Patrick Pauwels; Peter B Vermeulen; Luc Y Dirix; Steven J Van Laere Journal: PLoS One Date: 2010-09-07 Impact factor: 3.240
Authors: Diego M Marzese; Richard A Scolyer; Maria Roqué; Laura M Vargas-Roig; Jamie L Huynh; James S Wilmott; Rajmohan Murali; Michael E Buckland; Garni Barkhoudarian; John F Thompson; Donald L Morton; Daniel F Kelly; Dave S B Hoon Journal: Neuro Oncol Date: 2014-06-26 Impact factor: 12.300